J. Lipid Res.  Neurobiology of Lipids (ISSN1683-5506)
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Khoo, C.
Right arrow Articles by Sacks, F. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Khoo, C.
Right arrow Articles by Sacks, F. M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

The Journal of Lipid Research, Vol. 40, 202-212, February 1999
Copyright © 1999 by Lipid Research, Inc.


Original Article

Effects of estrogenic oral contraceptives on the lipoprotein B particle system defined by apolipoproteins E and C-III content

Christina Khooa, Hannia Camposa, Helena Judgea, and Frank M. Sacksa,b
a Department of Nutrition, Harvard School of Public Health, Boston, MA 02115
b Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115

Correspondence to: Frank M. Sacks

Apolipoproteins E and C-III are modulators of lipoprotein metabolism that could affect development of atherosclerosis. The prevalence in plasma of apoB-containing particles (LpB) that contain either apoE or apoC-III, both or neither, and the effect of estrogen on these lipoproteins are unknown. The LpB particle system, defined by the presence or absence of apoE or C-III, was studied in 13 normolipidemic women, 7 nonusers and 6 users of oral contraceptives. Fasting plasma was separated by anti-apoE and C-III affinity chromatography and ultracentrifugation into four types of VLDL, IDL, and LDL particles: with apoE but not apoC-III (E+C-), apoC-III but not apoE (E-C+), both (E+C+) or neither (E-C-). The predominant VLDL particles were E-C- (42% in nonusers, 56% in users) and E+C+ (39% in nonusers, 24% in users), suggesting that apoE and apoC-III mainly exist together in VLDL. In IDL, E-C- was the major fraction (74% nonusers, 81% users), and in LDL, it was 99% in both groups. The triglycerides in VLDL and IDL were mainly contained in C+ particles (79% and 66% of the total VLDL and IDL triglycerides, respectively). Within VLDL, IDL, and LDL, E-C- particles had the smallest size and E+C+ or E-C+ the largest. Users had higher concentrations of VLDL E-C- (280%) and IDL E-C- (90%) particles than nonusers. They also had higher free cholesterol and cholesteryl ester concentrations associated with these fractions and with VLDL E-C+. The triglyceride contents of VLDL E-C- particles were lower in users of oral contraceptives than in nonusers.

This study demonstrates that the elevated VLDL TG concentrations in users of estrogen-dominant oral contraceptives is mainly caused by an increased concentration of small VLDL particles that have reduced TG content, and that do not have apoE and C-III. These particles may have lower atherogenicity than particles enriched with apoE and C-III.—Khoo, C., H. Campos, H. Judge, and F. M. Sacks. Effects of estrogenic oral contraceptives on the lipoprotein B particle system defined by apolipoproteins E and C-III content. J. Lipid Res. 1999. 40: 202–212.

Supplementary key words: apoB, apoE, apoC-III, estrogen, oral contraceptives, atherosclerosis, lipoproteins, triglyceride, cholesterol


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Am. J. Clin. Nutr.Home page
C. Zheng, C. Khoo, J. Furtado, K. Ikewaki, and F. M Sacks
Dietary monounsaturated fat activates metabolic pathways for triglyceride-rich lipoproteins that involve apolipoproteins E and C-III
Am. J. Clinical Nutrition, August 1, 2008; 88(2): 272 - 281.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
C. Zheng, C. Khoo, K. Ikewaki, and F. M. Sacks
Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions
J. Lipid Res., May 1, 2007; 48(5): 1190 - 1203.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
C. Zheng, S. J. Murdoch, J. D. Brunzell, and F. M. Sacks
Lipoprotein Lipase Bound to Apolipoprotein B Lipoproteins Accelerates Clearance of Postprandial Lipoproteins in Humans
Arterioscler. Thromb. Vasc. Biol., April 1, 2006; 26(4): 891 - 896.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. E. Chiuve, L. A. Martin, H. Campos, and F. M. Sacks
Effect of the Combination of Methyltestosterone and Esterified Estrogens Compared with Esterified Estrogens Alone on Apolipoprotein CIII and Other Apolipoproteins in Very Low Density, Low Density, and High Density Lipoproteins in Surgically Postmenopausal Women
J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2207 - 2213.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S.-J. Lee, H. Campos, L. A. Moye, and F. M. Sacks
LDL Containing Apolipoprotein CIII Is an Independent Risk Factor for Coronary Events in Diabetic Patients
Arterioscler. Thromb. Vasc. Biol., May 1, 2003; 23(5): 853 - 858.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
J. Kovar and R. J. Havel
Sources and properties of triglyceride-rich lipoproteins containing apoB-48 and apoB-100 in postprandial blood plasma of patients with primary combined hyperlipidemia
J. Lipid Res., July 1, 2002; 43(7): 1026 - 1034.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
K. Tomiyasu, B. W. Walsh, K. Ikewaki, H. Judge, and F. M. Sacks
Differential Metabolism of Human VLDL According to Content of ApoE and ApoC-III
Arterioscler. Thromb. Vasc. Biol., September 1, 2001; 21(9): 1494 - 1500.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
H. Campos, D. Perlov, C. Khoo, and F. M. Sacks
Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia
J. Lipid Res., August 1, 2001; 42(8): 1239 - 1249.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
F. M. Sacks, P. Alaupovic, L. A. Moye, T. G. Cole, B. Sussex, M. J. Stampfer, M. A. Pfeffer, and E. Braunwald
VLDL, Apolipoproteins B, CIII, and E, and Risk of Recurrent Coronary Events in the Cholesterol and Recurrent Events (CARE) Trial
Circulation, October 17, 2000; 102(16): 1886 - 1892.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 1999 by the American Society for Biochemistry and Molecular Biology.